Services
APIs
Better reliability with backward integration
Leading the market in APIs
With over 30 years of manufacturing expertise, Truworth produces over 80 APIs at 12 production facilities, accounting for nearly 25% of our turnover. Our core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness in a dynamic market. Truworth has also emerged as one of India’s top exporters of APIs, serving over 70 countries around the globe.
Our manufacturing leadership extends across Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan (anti-hypertensive), Metoprolol Succinate (anti-hypertensive), Metoprolol Tartrate (anti-hypertensive), Pyrantel Salts (anthelmintic), and Propranolol (anti-hypertensive) – besides being one of the largest suppliers of these APIs worldwide.
Our product development teams work closely with our marketing teams to produce inventive concepts and ideas, tapping both market needs and synergies across therapeutic domains. To that end, the major activities and expertise of this division includes:
Chemical Research
- New and alternative cost-effective process routes
- Non-infringing processes
- Increasing plant friendliness
- Green chemistry
- Novel polymorphs / derivatives
- Productivity enhancement through continuous batch
- Flow-through continuous process chemistry
- Process engineering
- Impurity and standards synthesis
Analytical Research
- Method development
- Method validation
- Impurity profiling of APIs
- Regulatory compliance meeting global standards
Biosimilar Development
- Focused on r-DNA technology driven products, mainly mAbs, with higher dose of ‘R’ in R+D
- Collaborations with international academic institutes to help remain in the forefront of R&D
- Capabilities / Strengths:
- Cell engineering for high expression and robust platform development
- Process development capabilities from R&D to pilot scale
- Full-fledged formulation, bio-assay and analytical facility
Bio-processing & Metabolic Engineering
- Already a success story in developing and commercialising microbial (bacteria / yeast / fungi / actinomycetes) fermentation products, inaccessible by chemistry alone
- The focus of this unit is to develop strong pipeline of fermentation products to reduce dependency on imports
- Application of Synthetic Biology for developing novel strains giving significant commercial benefits will be the priority for the near future
New Drug Discovery and Development:
- Discovering New Chemical Entities (NCEs)
- Drug repurposing and improvements
- Collaborating with international research organisations
- Current pipeline includes pain-management, anti-platelets and antimalarials
- Few of the NCEs are advanced to clinical & preclinical development phases
- One of the novel molecules (AT-10) has shown very promising anti-platelet activity and is currently in clinical Phase-I trial in USA and India
- Another molecule (Atoguanil) is under clinical development in collaboration with MMV for seasonal malaria chemo-prevention
Intellectual Property Management
- Supported by qualified and expert IPR personnel
- Freedom to operate analysis for the in-house APIs
- Non-infringement alternatives
Awards & Recognition
Our research expertise has not only bagged us tremendous business opportunities, but also earned us unparalleled trust of our partners, and admiration of the industry at large. It has been appreciated in various forums and rewarded:
- CPhI Pharma Excellence Award – Madrid, 2018
- Our inventions have been continuously recognised:
- Best patent award from Pharmexcil in the years 2008, 2009, 2010, 2012, 2013, and 2014
- Best patent award from IDMA in the years 2008, 2009, 2014, and 2016